Abstract
Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.
| Original language | English (US) |
|---|---|
| Journal | Chest |
| Volume | 137 |
| Issue number | 6 SUPPL. |
| DOIs | |
| State | Published - Jun 1 2010 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
Cite this
Pulmonary hypertension in China : Pulmonary vascular disease: The global perspective. / Zhai, Zhenguo; Wang, Jun; Zhao, Lan; Yuan, Jason; Wang, Chen.
In: Chest, Vol. 137, No. 6 SUPPL., 01.06.2010.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pulmonary hypertension in China
T2 - Pulmonary vascular disease: The global perspective
AU - Zhai, Zhenguo
AU - Wang, Jun
AU - Zhao, Lan
AU - Yuan, Jason
AU - Wang, Chen
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.
AB - Significant progress has been made in understanding the pathogenesis of pulmonary hypertension (PH) and developing therapeutic approaches for PH in recent years. Most of the currently available data regarding the prevalence, diagnosis, treatment, and prognosis of PH are from American and European populations. Whether these data are also valid in the Chinese population is still controversial. China has a relatively large population of patients with PH for clinical and basic research. However, many medical centers and hospitals in China have limited experience with PH diagnosis and treatment. Given the potential higher prevalence of PH in China than in the United States and European countries, it is critical to develop suitable, effective, and novel therapeutic approaches for Chinese patients. Measures for the detection and prevention of PH need to be put in place urgently for the management of PH in China.
UR - http://www.scopus.com/inward/record.url?scp=77953314041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953314041&partnerID=8YFLogxK
U2 - 10.1378/chest.09-2802
DO - 10.1378/chest.09-2802
M3 - Article
C2 - 20522582
AN - SCOPUS:77953314041
VL - 137
JO - Chest
JF - Chest
SN - 0012-3692
IS - 6 SUPPL.
ER -